Bulletin
Investor Alert

New York Markets Close in:

Market Pulse Archives

May 16, 2022, 9:13 a.m. EDT

Mizuho: Lilly's newly approved diabetes drug expected to bring in $14 billion in sales by 2030

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Eli Lilly & Co. (LLY)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

The Food and Drug Administration on Friday approved Eli Lilly & Co.'s /zigman2/quotes/200106384/composite LLY +0.33% Mounjaro, a once-weekly injection for adults with type 2 diabetes. Patients enrolled in the Phase 3 clinical trial reported that the therapy reduced hemoglobin A1C between 1.8% and 2.4%, depending on the dose. Lilly also said it helped people lose between 12 and 25 pounds, though weight loss is not included on the FDA label. Approximately 30 million people in the U.S. have type 2 diabetes. "We find it noteworthy that the FDA sees Mounjaro's approval as meaningful enough to put out their own press release highlighting the news, while using language that we believe speaks to the transformative potential of the product," Mizuho Americas analysts told investors. Analysts there expect Mounjaro to generate more than $14 billion in sales by 2030. Lilly's stock has gained 5.5% this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -0.09% is down 15.5%.

/zigman2/quotes/200106384/composite
US : U.S.: NYSE
$ 328.26
+1.08 +0.33%
Volume: 1.04M
July 6, 2022 1:06p
P/E Ratio
48.59
Dividend Yield
1.20%
Market Cap
$310.87 billion
Rev. per Employee
$837,794
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,827.97
-3.42 -0.09%
Volume: 999.43M
July 6, 2022 1:06p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.